Phase 1 trial of brentuximab vedotin in combination with gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, a Children’s Oncology Group report.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 8544-8544 ◽  
Author(s):  
Peter D. Cole ◽  
Monika Metzger ◽  
Richard A. Drachtman ◽  
Terzah M. Horton ◽  
Xiaowei Liu ◽  
...  
Keyword(s):  
Young Adult ◽  
Hodgkin Lymphoma ◽  
Phase 1 ◽  
Brentuximab Vedotin ◽  
Adult Patients ◽  
Oncology Group ◽  
Phase 1 Trial ◽  
Group Report ◽  
Refractory Hodgkin Lymphoma

scholarly journals INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA

2017 ◽  
Vol 35 ◽  
pp. 85-86 ◽  
Author(s):  
A.F. Herrera ◽  
A.J. Moskowitz ◽  
N.L. Bartlett ◽  
J.M. Vose ◽  
R. Ramchandren ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Phase 1 ◽  
Brentuximab Vedotin ◽  
Refractory Hodgkin Lymphoma

scholarly journals A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Blood ◽  
2015 ◽  
Vol 125 (26) ◽  
pp. 4024-4031 ◽  
Author(s):  
Achim Rothe ◽  
Stephanie Sasse ◽  
Max S. Topp ◽  
Dennis A. Eichenauer ◽  
Horst Hummel ◽  
...  
Keyword(s):  
Natural Killer Cells ◽  
Natural Killer ◽  
Hodgkin Lymphoma ◽  
Phase 1 ◽  
Brentuximab Vedotin ◽  
Phase 1 Study ◽  
Killer Cells ◽  
New Approach ◽  
Key Points ◽  
Refractory Hodgkin Lymphoma

Key Points The bispecific, tetravalent antibody AFM13 represents a new approach engaging natural killer cells via CD16A to fight CD30+ malignancies. AFM13 is well tolerated and active in Hodgkin lymphoma patients who received all standard therapies, including brentuximab vedotin.

scholarly journals Successful rapid desensitization to the antibody–drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma

2015 ◽  
Vol 22 (1) ◽  
pp. 188-192 ◽  
Author(s):  
Marie Fizesan ◽  
Christopher Boin ◽  
Olivier Aujoulat ◽  
Georges Newinger ◽  
Dana Ghergus ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Brentuximab Vedotin ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Refractory Hodgkin Lymphoma ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document